CALL FOR ABSTRACTS

★ Abstract Submission Deadline: November 19, 2020 ★ Late-Breaking and Clinical Trials APRIL 9-14, 2021 Abstract Submission Deadline: January 11, 2021

Continuing Medical Education Activity - AMA PRA Category 1 Credits™ available

DISCOVERY SCIENCE DRIVING AACR.ORG ★ #AACR21 CLINICAL BREAKTHROUGHS TABLE OF CONTENTS

2 Key Dates

3 Welcome

4 Scientific Program APRIL 9-14, 2021 Plenary Sessions Major Symposia Advances Sessions Forums Educational Program

DISCOVERY 8 Policy Sessions SCIENCE 9 Spotlight on Clinical Trials DRIVING CLINICAL 10 Professional Advancement Opportunities BREAKTHROUGHS 11 Continuing Medical Education (CME)

12 Survivor and Patient AACR OFFICERS Advocacy Program President 13 Press Coverage and Social Media Antoni Ribas President-Elect 14 Financial Support for Attendance David A. Tuveson

Treasurer 16 Guidelines for Preparation and William N. Hait Submission of Abstracts Immediate Past President Elaine R. Mardis 19 Abstract Categories

Chief Executive Officer Margaret Foti 24 AACR Membership Opportunities

Board of Directors 26 General Information Adriana Albini Scott A. Armstrong 28 Annual Meeting Committees René Bernards Marcia R. Cruz-Correa Keith T. Flaherty Silvia Chiara Formenti Elaine Fuchs ABOUT THE COVER IMAGE: Roy S. Herbst Carl H. June ©2020 American Association for Cancer Research Karen E. Knudsen Inside of sphere (clockwise): AACR Virtual Special Conference: Edison T. Liu Epigenetics and Metabolism art; Glioblastoma (iStock); DNA sequencing (Getty) Ira Mellman Foreground of sphere (clockwise): 3D render of T cells attacking cancer cells (Getty); Martine F. Roussel 3D illustration of a method of DNA sequencing (Getty); Medical 3D illustration of a dividing cancer cell (Getty) Charles Swanton Suzanne L. Topalian

AACR.org/AACR2021 ★ #AACR21 ★ 1 AACR ANNUAL MEETING 2021 KEY DATES

September 30, 2020 Abstract Submission Opens

October 13, 2020 Application Deadline: NextGen Stars

November 12, 2020 Membership Application Deadline for Regular Abstract Sponsors and Scholar-in-Training Award Applicants

November 19, 2020 Regular Abstract Submission Deadline (11:59 p.m. ET)

November 19, 2020 Application Deadlines: AACR Global Scholar-in-Training Awards AACR Minority-Serving Institution Faculty Scholar in Cancer Research Awards AACR Minority Scholar in Cancer Research Awards AACR Scholar-in-Training Awards AACR Women in Cancer Research Scholar Awards

December 18, 2020 Late-Breaking and Clinical Trials Abstract Submission Opens

January 6, 2021 Online Itinerary Planner Available

January 7, 2021 Membership Application Deadline for Late-Breaking and Clinical Trials Abstract Sponsors

January 11, 2021 Late-Breaking and Clinical Trials Abstract Submission Deadline (11:59 p.m. ET)

February 1, 2021 Regular Abstract Status Notifications Sent

February 4, 2021 Submission Deadline: Final Data for Clinical Trial Placeholder Abstracts

February 10, 2021 Late-Breaking and Clinical Trials Abstract Notifications Sent

February 22, 2021 Regular Abstract Withdrawal Deadline

March 9, 2021 Late-Breaking and Clinical Trials Abstract Withdrawal Deadline

March 17, 2021 Annual Meeting App Available for Download

April 9, 2021 AACR Annual Meeting Begins (12:00 p.m. ET)

April 9, 2021 Late-Breaking and Clinical Trials Abstract Texts Posted to Online Itinerary Planner and Meeting App

AACR.org/AACR2021 ★ #AACR21 ★ 2 AACR ANNUAL MEETING 2021 WELCOME

Dear Members and Friends of the AACR, We are pleased to announce the Call for Abstracts for the 112th Annual Meeting of the American Association for Cancer Research (AACR). Reflecting the theme of this year’s meeting, “Discovery Science Driving Clinical Breakthroughs,” the scientific program will span the broad spectrum of cancer science and medicine from basic, translational, and clinical research including cancer health disparities; to early detection, interception, prevention, and population science; to regulatory science and policy. The Opening Plenary Session will address the theme of the meeting and will include presentations on lineage tracing of tumor metastasis, tumor metabolism, genomic sequencing in diverse populations, immune surveillance, antitumor immune response, and clinical implications. New this year is the Discovery Science Plenary Session, which will focus on the mechanisms, impact, and exploitation of cancer chromosomal instability for potential therapeutic intervention. Also, a comprehensive educational program of more than 60 educational sessions and methods workshops, covering a wide array of disciplines and new technologies, is currently under development. Major progress against cancer has been realized over the past few decades due to remarkable scientific advances and multidisciplinary collaborations, and during this year a record number of new cancer treatments were approved by the U.S. Food and Drug Administration. However, during the COVID-19 pandemic, many labs were forced to close, and clinics have needed to shift resources and refocus efforts to combat this enormous public health crisis. There is now much concern that the delays in cancer screening, diagnosis, and treatment because of the COVID-19 pandemic will have a significant negative impact on the pace of progress against cancer and on cancer patient outcomes. Now more than ever it is critically important to focus our collective efforts and resources on our mission to prevent and cure all cancers. Despite these challenges, this has been a transformative year for the global cancer research community – one that has resulted in a new wave of scientific innovation that will be reflected in our Annual Meeting program. The year 2021 will be an exciting time for us to celebrate the 50th Anniversary of the signing of the National Cancer Act. The signing of this Act was a pivotal moment in history, as it has led to the formation of highly impactful comprehensive cancer centers in the U.S., the development of education and training programs for early-career laboratory and clinical investigators, increased funding for innovative cancer research, and many cancer breakthroughs that have saved millions of lives from the disease. Proffered oral and poster presentations selected from submitted abstracts are a vital part of our Annual Meeting. For your interest, a new abstract category for research on COVID-19 and cancer has been added to our Call for Abstracts. We look forward to receiving your submissions and to providing an interactive venue for you to share your important work. Your participation in the 2021 Annual Meeting will not only be a welcome addition to the program, but it will also maximize collaborations, stimulate creative thinking about how to accelerate progress against cancer, and contribute greatly to the cause. The regular abstract deadline is November 19, 2020. Our proffered program also features special oral presentation opportunities in several Clinical Trial Plenary Sessions for abstracts reporting on high-impact clinical trials. The deadline for late-breaking abstracts and clinical trial abstracts is January 11, 2021. Please note that recently, the AACR Board of Directors approved an expansion of the abstract sponsorship privileges for certain AACR member types. We encourage AACR members to use their additional privileges to sponsor abstract submissions from their mentees and nonmember colleagues. Please view the details of these expanded privileges on page 18. The AACR will also continue to offer special presentation opportunities for early-career scientists. All AACR Associate Members, as well as Active Members at the assistant professor level or equivalent, may apply to the NextGen Stars Program to be considered for the honor of presenting their work in one of the major sessions during the meeting. Interested members must submit an abstract along with supporting materials by October 13, 2020. Please check the AACR website (AACR.org/AACR2021) regularly for program updates and other meeting announcements. During these difficult times our heartfelt sympathies are extended to everyone who has been impacted by this global health crisis. It is our sincere hope that we will all be able to gather in person in 2021 to discuss your innovative work across the full spectrum of cancer research. We look forward to receiving your abstract submissions and to your active participation in AACR Annual Meeting 2021. With best wishes and regards,

Antoni Ribas, MD, PhD, FAACR Charles Swanton, FRCP, BSc, PhD, FAACR President, 2020-2021 Chair, 2021 Program Committee

AACR.org/AACR2021 ★ #AACR21 ★ 3 AACR ANNUAL MEETING 2021 SCIENTIFIC PROGRAM

WHY YOU SHOULD ATTEND THE PLENARY SESSIONS WORLD’S MOST IMPORTANT Saturday, April 10, 2021 CANCER RESEARCH MEETING DISCOVERY SCIENCE PLENARY SESSION: The AACR Annual Meeting highlights the work of MECHANISMS, IMPACT, AND EXPLOITATION OF the greatest minds in cancer science and medicine CANCER CHROMOSOMAL INSTABILITY from institutions all over the world. This meeting David Pellman, Dana-Farber Cancer Institute, Boston, MA presents the many scientific discoveries across the breadth of cancer research—from prevention, Angelika Amon, Massachusetts Institute of early detection, and interception; to cancer biology Technology, Cambridge, MA and genetics, translational, and clinical studies; to Stephen P. Jackson, University of Cambridge, survivorship, population science, and advocacy. You Cambridge, United Kingdom will be exposed to the latest developments in all areas of cancer research, form new collaborations, and Additional speaker to be announced. learn how to apply exciting new concepts, tools, and techniques to your own research. Sunday, April 11, 2021 This year’s program, with the theme of “Discovery Science Driving Clinical Breakthroughs,” will be a OPENING PLENARY SESSION: DISCOVERY SCIENCE comprehensive, cutting-edge scientific event that you DRIVING CLINICAL BREAKTHROUGHS will not want to miss! Chair: Charles Swanton, The Francis Crick Institute, London, United Kingdom Jonathan S. Weissman, University of California, PROGRAM IN PROGRESS San Francisco, CA Karen H. Vousden, The Francis Crick Institute, London, Beginning at 3:00 p.m. on Friday, April 9, and United Kingdom continuing until 3:30 p.m. on Saturday, April 10, 2021, a program of Educational Sessions and Methods Matthew G. Vander Heiden, Massachusetts Institute of Workshops will be presented. An Educational Program Technology, Cambridge, MA Pass granting access to the complete educational Melissa B. Davis, Weill Cornell Medical College, New program will be available for purchase when York, NY registration opens. On Saturday at 3:45 p.m. an exciting new Discovery Science Featured Plenary Mark A. Dawson, Peter MacCallum Cancer Centre, Session will be open to all registrants. The Opening Melbourne, Australia Ceremony and the Opening Plenary Session will Zhijan James Chen, UT Southwestern Medical School, take place on Sunday morning, April 11. The Dallas, TX meeting will conclude at 1:30 p.m. on Wednesday, April 14. Abstracts submitted for the regular (November 19, 2020) or late-breaking and clinical trials (January 11, 2021) submission deadlines will be considered for short talks or ePoster presentations. The 2021 Program in Progress follows; additional exciting and timely invited sessions are being developed and will be posted at AACR.org/AACR2021.

AACR.org/AACR2021 ★ #AACR21 ★ 4 AACR ANNUAL MEETING 2021 SCIENTIFIC PROGRAM Plenary Sessions (cont’d)

Monday, April 12, 2021 MAJOR SYMPOSIA UNDERSTANDING THE MOLECULAR AND AACR-Bayard D. Clarkson Symposium on Stem Cells, MICROENVIRONMENTAL DETERMINANTS OF Leukemia, and the Niche CANCER Advances in Cancer Nanotechnology Chair: Christina Curtis, Stanford University, Stanford, CA Alternative DNA Repair Pathways and Their Drug Targets Garry P. Nolan, Stanford University School of Medicine, Stanford, CA Artificial Intelligence in Cancer Imaging Serena Nik-Zainal, University of Cambridge, Artificial Intelligence/Machine Learning in Cancer Cambridge, United Kingdom Research and Care: Progress and Opportunities Ross L. Levine, Memorial Sloan Kettering Cancer Cancer Immunometabolism Center, New York, NY Colorectal Cancer Interception: Immunologic and Jérôme Galen, INSERM, Paris, France Pharmacologic Advances COVID-19 and Cancer Research

Tuesday, April 13, 2021 Cytokine Receptors in Immuno-oncology: Discovery, Analysis, and Modulation CANCER BIOLOGY AND THE CHANGING THERAPEUTIC LANDSCAPE Deubiquitylating Enzymes as Targets for Cancer Therapy Chair: Sheila A. Stewart, Washington University, St. Louis, MO Developing Rational Combinations of Targeted Drugs Tony Hunter, Salk Institute, La Jolla, CA Diet, Clock, and Cancer William G. Kaelin, Jr., Dana-Farber Cancer Institute, Drugging KRAS Boston, MA Engineering and Modulating Natural Killer Cells for Olufunmilayo I. Olopade, University of Chicago Cancer Immunotherapy Medicine Comprehensive Cancer Center, Chicago, IL Familial Predisposition: Precision Medicine and Dennis J. Slamon, UCLA David Geffen School of Targeted Therapy Medicine, Los Angeles, CA From ‘Omics Data to Prognostic and Predictive Biomarkers

Wednesday, April 14, 2021 Functional Precision Medicine in Cancer LEVERAGING THE IMMUNE SYSTEM IN Germline Influence on Immunotherapy Outcomes THE WAR ON CANCER Implications of Clonal Hematopoiesis in Human Health Chair: Nina Bhardwaj, Icahn School of Medicine at Improving Therapy through Normalization of the Mount Sinai, New York, NY Tumor Microenvironment Anjana Rao, La Jolla Institute for Immunology, Matrix, Exosomes, and TME Cells in the Metastatic La Jolla, CA Niche Sergio A. Quezada, University College London Cancer Mechanisms and Biomarkers of Response and Institute, London, United Kingdom Resistance to Immunotherapy Michel Sadelain, Memorial Sloan Kettering Cancer Metabolism and Chromatin Deregulation in Center, New York, NY Cancer and Cancer Heterogeneity Additional speaker to be announced. Modeling Metastatic Progression in the Mouse Molecular Imaging Neoadjuvant Immunotherapy for Melanoma and Other Cancers

AACR.org/AACR2021 ★ #AACR21 ★ 5 AACR ANNUAL MEETING 2021 SCIENTIFIC PROGRAM Major Symposia (cont’d)

New Approaches to Chimeric Antigen Receptor DNA Damage Response (DDR) Treatment: Evolving Engineering Diagnostic Approaches, Understanding of Replication Stress, and Resistance Mechanisms to DDR Targeting New Combinations of Targeted Therapies and Therapies Immunotherapies Hybrid Technologies for Cancer Imaging, Theranostics, Next Frontiers in Adjuvant Therapy and Image-Guided Interventions Next-Generation Epigenetic Drugs Management of Toxicity of Immune Cell Therapy Options and Opportunities for Treating Metastasis Noninvasive Monitoring of Minimal Residual Disease Paracrine Signaling in Cancer with Liquid Biopsies: Toward Real-Time Treatment Decision-Making Phase Separation, Transcription, and Cancer Proton Therapy and FLASH Irradiation Progress from Personalized Cancer Vaccine Trials Targeting Transcriptional Cyclin-Dependent Kinases T Cells in Cancer in Cancer The Cancer Dependency Map Translational Canine Models Advancing The Clinical Proteomic Tumor Analysis Consortium: Immunotherapy and Immunogenomics Building a Proteogenomic Atlas of Cancer Understanding and Overcoming Resistance to Third The Microbiome in Cancer Therapy: Hype or Hope? Generation EGFR and ALK Inhibitors The Tumor Microbiome and Its Role in Oncogenesis and Modulating Therapy Response Toward Engineering of Neoantigen-Specific T-Cell Therapies ADVANCES IN ORGAN SITE RESEARCH Tumor Cell Plasticity and Resistance to Advances in Endometrial Cancer Cancer Therapies Advances in Sarcoma Therapy Tumor Hypoxia and Genetic Instability: New Mechanisms and New Targets Developing More Effective Treatments for Triple- Negative Breast Cancer When Is Transforming Growth Factor Beta Targetable? Diffuse Large B-Cell Lymphoma AACR-ASCO Joint Session: Targets in the Treatment of Renal Cell Cancer Emerging Concepts in Liver Cancer Research AACR-CSCO Joint Symposium: Single-Cell Analysis— Next-Generation Treatments for Melanoma: Building Changing the Landscape of Cancer Research on Success AACR-JCA Joint Session: Tracking Tumor Evolutionary Pathways to Early Detection of Pancreatic Cancer Dynamics: From Initiation through Metastasis Solid Tumor Brain Metastasis AACR-ONS Special Session: Symptom Science Targeting Signaling Pathways in Colorectal Cancer Therapeutic Advances in Biliary Tract Cancers Therapeutic Vulnerabilities and Resistance ADVANCES IN DIAGNOSTICS Mechanisms in Estrogen Receptor-Positive AND THERAPEUTICS Breast Cancer Advances in Drug Delivery Computational Methods for Immunogenomics and Precision Oncology Diagnostic Tests for Immunotherapy: Current CLIA Lab Testing and Future Directions

AACR.org/AACR2021 ★ #AACR21 ★ 6 AACR ANNUAL MEETING 2021 SCIENTIFIC PROGRAM (cont’d)

ADVANCES IN PREVENTION, EDUCATIONAL PROGRAM: EARLY DETECTION, AND EDUCATIONAL SESSIONS AND INTERCEPTION METHODS WORKSHOPS Connecting the Tumor Microenvironment with the Educational programming will begin on Friday, Macroenvironment in Cancer Cachexia April 9, at 3:00 p.m. and continue through 3:30 p.m. on Saturday, April 10. The Educational Program is an Interception of Preneoplasia integral part of the meeting and provides attendees Molecular Targets of Precision Prevention and with an opportunity to expand their knowledge Interception base. Meeting registrants will be able to purchase an Educational Program Pass granting access to Panel on Rural Cancer Control the complete educational program of more than 65 Radiation-Induced Cancers and Cancer Survivorship unique sessions covering all areas of cancer research, including the popular multisession programs noted below. More information about the Educational Program and the Educational Program Pass will be available at . ADVANCES IN THE SCIENCE OF AACR.org/AACR2021 CANCER HEALTH DISPARITIES ★ Tumor Immunology and Immunotherapy for Nonimmunologists. Annually, this two-part series Carcinogenic Exposures and Global Cancer Prevention combines a comprehensive review of a hot topic Pan-Cancer Distinctions in Tumor Biology across in the field with a roundtable session that enables Ethnicity and Genetic Ancestry attendees to participate in group discussions with leading experts in the field. Precision Medicine in Underserved Populations ★ Chemistry to the Clinic. This three-part series provides attendees with foundational knowledge of critical elements of the drug development process, such as lead optimization, identification of targets, FORUMS and drug modalities. Are Antitumor T Cells Exhausted or Dysfunctional? ★ Clinical Trial Design. Over the course of three Does It Matter? consecutive sessions, this Methods Workshop Are There Cancer Stem Cells? will provide attendees with a historical and methodologic understanding of clinical trials and Biostatistics Debate: Should Science Be Guided by demonstrate how to design an appropriate trial P-Values? to answer the scientific questions presented by Cancer Cell Dormancy: The Current Paradigm and the emerging treatments. Challenges Ahead to Develop New Therapies Additional details will be posted at CAR T-Cell Therapy or T-Cell Engager? AACR.org/AACR2021. Data Science and Machine Learning: Will They Revolutionize Cancer Cure and Research? Embracing Entrepreneurship in Cancer Research Microbiome Pandemonium: Checkpoints and the Microbiome Patient-Derived Models for Cancer The Myths and Realities of the Abscopal Effects What Is the Role for Oncolytic Viruses in Cancer Treatment?

AACR.org/AACR2021 ★ #AACR21 ★ 7 AACR ANNUAL MEETING 2021 POLICY SESSIONS

Decisions made by policymakers in Washington, The Regulatory Science and Policy Track includes DC, have a direct impact on cancer research and the informative sessions designed to highlight recent progress being made against cancer in the United regulatory developments and provide an open States and throughout the world. The AACR sponsors forum for the consideration of issues that the FDA sessions with policymakers, academic researchers, faces as the agency seeks to accelerate the pace of patient advocates, cancer survivors, and industry approval of safe and effective treatments for patients representatives to foster dialogue about emerging with cancer. These sessions offer an opportunity for topics in science and health policy, and regulatory attendees to discuss cutting-edge issues in cancer science and policy. drug, biologic, and diagnostic regulation with stakeholders from academia, industry, advocacy, and The Science and Health Policy Track includes government. Past regulatory science and policy sessions that will provide attendees with an topics have included strategies for increasing opportunity to learn about how policy impacts science participation of underrepresented populations in and vice versa. Science policy sessions will examine clinical trials, guidance for using real-world evidence the current political environment affecting federal to support clinical trials during the COVID-19 funding for the NIH and NCI, including highlighting pandemic, regulatory considerations for developing ways for scientists to get involved in advocating for liquid biopsy tests, implications of site-agnostic robust, sustained, and predictable budget increases. therapy approval for drug development, and Health policy sessions will explore how scientific applications for artificial intelligence/machine learning evidence can inform policy on cancer prevention in regulatory decision-making. and control and what impact policies are having on patients and communities. Past health policy sessions The Science of Survivorship Track includes sessions have covered topics such as e-cigarettes and tobacco highlighting new and high-value areas of research control measures, the Affordable Care Act, and ways to address the array of challenges facing long- to prevent and control pathogen-related cancers, such term cancer survivors. Sessions invite trans-sector as increasing the use of the human papillomavirus discussion among the survivor and advocacy (HPV) vaccine. communities, basic and clinical researchers, industry representatives, health care providers, and government officials. Past science of survivorship topics have included aging and cancer, long-term survivorship and vulnerable populations, development of new survivorship models, patient-reported outcomes, data sharing, and patient engagement.

AACR.org/AACR2021 ★ #AACR21 ★ 8 AACR ANNUAL MEETING 2021 SPOTLIGHT ON CLINICAL TRIALS

SUBMIT YOUR CLINICAL TRIALS WHAT TO SUBMIT ABSTRACTS TO THE AACR ★ Any phase (I, II, III, or any combination) abstract ANNUAL MEETING 2021 from national or international clinical trials Become a part of our growing clinical research ★ Promising ongoing trials, or unique trial designs program at the Annual Meeting and help us showcase that have not yet yielded results, to the Clinical how discovery science continues to transform the lives Trials in Progress category (CT08) of cancer patients. ★ Encore clinical trials presentations that have been presented solely in abstract form, including publication in conference proceedings. Submissions must include significant additional data from the WHY YOU SHOULD SUBMIT previous presentation (as determined by the ★ Numerous and unique oral presentation review committee). opportunities ★ COVID-19 and cancer clinical trials to the COVID-19 • Four Clinical Trials Plenary Sessions offering and Cancer (COVID06) or Clinical Trials (CT07) companion presentations discussing the science categories. behind the trials presented ★ See pages 21-22 for clinical trials (CT) abstract • Three Clinical Trials Minisymposia categories and visit AACR.org/AACR2021 for ★ Poster presentations (enhanced e-Posters with submission guidelines. opportunities for engagement) ★ Opportunities for extensive national media coverage through the AACR press program WHEN TO SUBMIT ★ Opportunities to simultaneously present your ★ Submit your completed or placeholder abstract(s) work and publish a manuscript in a high-impact by the January 11, 2021 deadline for clinical trials AACR journal and late-breaking abstracts. The clinical trials • Indicate your intention to submit a manuscript (CT) abstract categories will not be available for during the abstract submission process. submissions for the November 19, 2020 deadline. • Contact [email protected] with any questions. ★ Final results and conclusions for placeholder ★ No restrictions on presenters if the presentation is abstracts are due by February 4, 2021. CME-compliant

AACR VIRTUAL ANNUAL MEETINGS I AND II 2020 30 104 50 TRIALS IN CLINICAL TRIALS IN TRIALS IN PROGRESS PLENARY SESSIONS POSTER SESSIONS IN POSTER SESSIONS

AACR.org/AACR2021 ★ #AACR21 ★ 9 AACR ANNUAL MEETING 2021 PROFESSIONAL ADVANCEMENT OPPORTUNITIES

In support of its mission to promote the education PROFESSIONAL and training of cancer scientists and clinicians and to cultivate a highly skilled and diverse cancer research ADVANCEMENT SESSIONS workforce, the AACR provides Annual Meeting Exclusive Member Benefit attendees at all career stages—from high school and undergraduate students to senior investigators—with Professional Advancement Sessions have long opportunities to enhance and advance their careers. been an integral part of the AACR Annual Meeting For more information about any of the professional experience, representing the AACR’s dedication to development opportunities that follow, visit the education, training, and career advancement AACR.org/AACR2021 and click on the “Professional of cancer research investigators at all stages of their Development Opportunities” tab. careers. Each year, several interactive and engaging professional development and career advancement opportunities are organized to provide important skills to investigators at all levels, from students to senior faculty.

NEXTGEN STARS All Professional Advancement Sessions are free and exclusive to AACR members. There is no cost to Early-career scientists can apply to give a presentation join the AACR as a Student Member (high school in a Major Symposium or Advances Session at the students and undergraduates) or Associate Member AACR Annual Meeting 2021. Speaking slots are limited (graduate students, medical students and residents, and are only available to AACR Associate Members and clinical and postdoctoral fellows who are enrolled and to AACR Active Members who are not above the in education or training programs that could lead to level of assistant professor or equivalent. The NextGen a career in cancer research). If you are not an AACR Stars program provides an exciting opportunity to member, you are strongly encouraged to join and take increase the visibility of early-career scientists at the advantage of being able to attend these sessions and AACR Annual Meeting and to support the professional the many other benefits of membership, including development and advancement of those selected the privilege of sponsoring abstracts, and reduced to speak. member registration rates for the Annual Meeting 2021. Visit AACR.org/Membership to apply today! The deadline to submit applications is 12:00 p.m. U.S. ET, October 13, 2020. Applications consist Professional Advancement Sessions to be held at the of an extended abstract (limit 8,000 characters), Annual Meeting 2021 will be announced in the fall. a CV, and a letter of recommendation from a P.I., Visit AACR.org/PAS for session updates, including department head, or another mentor who is familiar opportunities for physician-scientists and early-career with the applicant’s work. Applicants selected as and early-stage investigators. NextGen Stars for 2021 will receive travel support and complimentary registration for the meeting. Details can be found at AACR.org/AACR2021 under the “NextGen Stars” tab.

AACR.org/AACR2021 ★ #AACR21 ★ 10 AACR ANNUAL MEETING 2021 CONTINUING MEDICAL EDUCATION (CME)

The AACR’s Continuing Medical Education (CME) Program brings the latest cancer research from “bench to bedside and back.” The AACR has been awarded Accreditation with Commendation status by the Accreditation Council for Continuing Medical Education (ACCME). The AACR CME Program consists of educational interventions designed to encourage the analysis and discussion of the latest findings in all areas of basic, translational, and clinical cancer research not only among researchers, but also by engaging clinicians in this scientific discourse. The AACR is committed to advancing the ability of clinicians to apply critical aspects of cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. The AACR Annual Meeting 2021 will be a Continuing Medical Education Activity and AMA PRA Category 1 Credits™ will be available. This is a great opportunity to complete your required credit hours.

MEET YOUR MOC POINT REQUIREMENTS

If you are a physician, you can meet your Maintenance of Certification (MOC) point requirements at the AACR Annual Meeting 2021. The meeting is CME/MOC accredited. Successful completion of the CME activity enables you to earn MOC points of the American Board of Internal Medicine’s (ABIM) Maintenance of Certification program.

AACR.org/AACR2021 ★ #AACR21 ★ 11 AACR ANNUAL MEETING 2021 SURVIVOR AND PATIENT ADVOCACY PROGRAM

AACR’S COMMITMENT TO AACR SCIENTIST↔SURVIVOR SURVIVORS AND PATIENT PROGRAM ADVOCATES A special advocacy program that the AACR hosts each The voices of patients with cancer have never year is the AACR Scientist↔Survivor Program (SSP), been more important than in today’s environment, which is now in its 23rd year. Led admirably since its especially as patients are partnering with researchers inception by Anna D. Barker, PhD, of the Lawrence by selflessly donating tissue and personal data to J. Ellison Institute for Transformative Medicine of advance progress. Additionally, patient advocates USC, SSP is designed to build enduring partnerships play a crucial role in educating the public about new among the leaders of the scientific, cancer survivor, research discoveries, serving on committees and and patient advocacy communities worldwide. The panels to inform cancer research and regulatory program has a competitive application process and policies, increasing awareness among legislators, and occurs twice each year, with the larger program being raising precious funds for cancer research. held in conjunction with the AACR Annual Meeting.

The AACR recognizes and celebrates the contributions This unique program provides an opportunity for of survivors and patient advocates to cancer research patient advocates to learn about cancer research and and policy and welcomes their attendance and to interact with scientists, physicians, health care participation at the AACR Annual Meeting. professionals, and other advocates.

Discounted registration rates are available for Specifically, patient advocate representatives come patient advocates. together to discuss the latest findings in cancer research, foster collaborative interdisciplinary partnerships, and promote progress in new research areas in the cancer field. Advocates benefit from special scientific lectures in lay terms; stimulating small group discussions; and other opportunities to exchange information on key aspects of cancer research, survivorship, advocacy, and public policy.

If you are interested in applying for this year’s SSP, please visit AACR.org/SSP2021 or contact us at [email protected].

Patient advocates can also engage with the AACR in many ways throughout the year, including through AACR’s magazine Cancer Today, the AACR Foundation, the annual AACR Cancer Progress Report, and by participating in advocacy days on Capitol Hill.

AACR.org/AACR2021 ★ #AACR21 ★ 12 AACR ANNUAL MEETING 2021 PRESS COVERAGE AND SOCIAL MEDIA

ATTRACTING JOURNALISTS UTILIZING SOCIAL MEDIA TO WORLDWIDE, GENERATING AMPLIFY THE CONVERSATION MAJOR NEWS COVERAGE The AACR Virtual Annual Meetings I and II 2020 also The AACR is the authoritative resource and voice generated significant social media activity in the for cancer research, and the AACR Annual Meeting cancer research community. Social media highlights garners the best in national and international news included: coverage. The AACR Virtual Annual Meetings I and II, held in April and June 2020, attracted a total of 174 AACR Virtual registered reporters. The two meetings showcased Annual Meeting I 2020: innovative clinical, translational, and basic research and generated nearly 2,500 media clips in leading 2,758 consumer and trade outlets including The Associated PEOPLE JOINING THE Press, The New York Times, The Washington Post, CONVERSATION ON TWITTER Reuters, STAT, and Science, among many others. All abstracts accepted for presentation at the meeting 9,003 will be considered for inclusion in the official AACR TOTAL TWEETS USING Annual Meeting 2021 press program. For more THE #AACR20 HASHTAG information on the AACR Annual Meeting press program, please contact Julia Gunther at julia.gunther@ aacr.org or Rick Buck at [email protected]. 45,427,000 TOTAL IMPRESSIONS

AACR Virtual Annual Meeting II 2020: 2,307 PEOPLE JOINING THE CONVERSATION ON TWITTER 7,065 TOTAL TWEETS USING THE #AACR20 HASHTAG 42,426,000 TOTAL IMPRESSIONS

AACR.org/AACR2021 ★ #AACR21 ★ 13 AACR ANNUAL MEETING 2021 FINANCIAL SUPPORT FOR ATTENDANCE

Through the generosity of its loyal supporters and AACR GLOBAL grants from the National Cancer Institute (NCI), the AACR is pleased to provide financial support SCHOLAR-IN-TRAINING AWARDS to meritorious undergraduate students and early- Global Scholar-in-Training Awards (GSITA) of career scientists residing anywhere in the world, and $2,000 are available for eligible early-career also to members of minority groups residing in the investigators in countries building cancer research United States and Canada that have been traditionally capacities. Applicants must submit an abstract to underrepresented in cancer research and biomedical the AACR Annual Meeting 2021 and then complete science, to assist them in attending the AACR Annual a separate GSITA application. Applicants must be Meeting. Detailed information about these award Associate Members of the AACR in good standing programs, including eligibility and selection criteria, can (membership current through 2020). Nonmember be found by visiting AACR.org/AACR2021 and clicking graduate students, medical students and residents, on the “Financial Support for Attendance” link. clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a GSITA should submit a Membership Application Form by November 12, 2020 before submitting their GSITA application. For additional details and a list of eligible developing AACR SCHOLAR-IN-TRAINING countries, visit AACR.org/GSITA. Application AWARDS deadline: November 19, 2020. Exclusive Member Benefit

Scholar-in-Training Awards are available for Associate Members in good standing who are the presenters of meritorious abstracts at the AACR Annual Meeting. AACR-MINORITIES IN CANCER These awards are made possible by the generosity of RESEARCH (MICR)-SPONSORED supporting foundations and corporations. Nonmember AWARDS graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows Minorities in Cancer Research (MICR)—a membership who wish to apply for a Scholar-in-Training Award group within the AACR—is working to increase the should submit their AACR membership applications number, participation, visibility, and recognition of by November 12, 2020. The AACR Membership minority scientists in cancer research. The AACR Application Form is available on the AACR website Minority and Minority-Serving Institution Faculty at AACR.org/Membership. To apply for a Scholar- Scholar Awards and Minority Scholar Awards are two in-Training Award, an applicant must first submit of several programs sponsored by MICR in support an abstract, and then complete a separate award of its mission. These awards are generously application. For details of the application process and supported by the NCI Center to Reduce Cancer the selection criteria, please visit AACR.org/SITA. Health Disparities. To learn more, please visit Application deadline: November 19, 2020. AACR.org/MICR or send an email to [email protected]. AACR Minority and Minority-Serving Institution (MMSI) Faculty Scholar in Cancer Research Awards: Full-time minority faculty and faculty of Minority- Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], American Indian Tribally-Controlled Colleges and Universities [AITCCUs], and other postsecondary institutions as defined by the U.S. Department of Education) who present a proffered paper at this conference are encouraged to apply for this meritorious scholar award for travel. Supported by a generous grant from the Center to Reduce Cancer

AACR.org/AACR2021 ★ #AACR21 ★ 14 AACR ANNUAL MEETING 2021 FINANCIAL SUPPORT FOR ATTENDANCE (cont’d)

Health Disparities of the NCI, the purposes of these AACR-WOMEN IN CANCER awards are to increase the scientific knowledge base of minority faculty and faculty at MSIs, to encourage RESEARCH (WICR) SCHOLAR them in their research, and to assist in inspiring their AWARDS students to pursue careers in cancer research. Only The AACR-Women in Cancer Research (WICR) Scholar citizens of the United States or Canada or scientists Award is a highly competitive award recognizing who are permanent residents of these countries may WICR members who are scientists-in-training and receive one of these awards. For details or to submit presenters of meritorious scientific papers at the an application, visit AACR.org/MSI. Application AACR Annual Meeting. The purpose of this award is deadline: November 19, 2020. to increase the scientific knowledge base of WICR AACR Minority Scholar in Cancer Research Awards: members and to encourage them to pursue careers Presenters of a proffered paper who are full-time in cancer research. All graduate students, medical predoctoral (graduate or medical) students, residents, students, residents, clinical fellows, and postdoctoral and clinical or postdoctoral fellows who are engaged fellows are welcome to apply. For details or to apply, in cancer research or have the training and potential visit AACR.org/WSA. Application deadline: to make contributions to this field are encouraged to November 19, 2020. apply for this meritorious scholar award for travel. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the NCI, this program applies only to racial/ethnic minority groups that have been identified by the NCI as being traditionally underrepresented in cancer and biomedical research, e.g., African American/Black, Alaskan Native, Hispanic/Latino, Native American, and Native Pacific Islander. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. For details or to submit an application, visit AACR.org/MSA. Application deadline: November 19, 2020.

“Excellent organization and presentation of talks. Delivery of talks was well orchestrated!”

AACR.org/AACR2021 ★ #AACR21 ★ 15 AACR ANNUAL MEETING 2021 GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS

AACR Abstract Submission System. Authors ★ Transfer of Copyright. On behalf of all authors, must submit abstracts for presentation at the the submitting author must assign and transfer Annual Meeting 2021 using the AACR Abstract copyright for the abstract to the AACR. Submission System, which will be available at ★ Presentation of Abstracts. The submitting author AACR.org/AACR2021 beginning September 30, 2020. for each abstract must designate a presenter who You can create, modify, and submit abstracts until agrees to register for the meeting and attend the the November 19, 2020, abstract deadline. Complete corresponding session to discuss in detail the instructions on the use of the AACR Abstract research presented in the published abstract. If the Submission System will be provided on the website. assigned presenter cannot attend the meeting, the Note for 2021: Submit your abstract detailing how you authors are expected to designate a replacement or use AACR Project GENIE data by the November 19, 2020, withdraw the abstract (see page 17). deadline for an opportunity to be featured in a special ★ Confirmation of No Prior Publication/ session during the Annual Meeting 2021. Simply include Presentation. Authors who submit an abstract GENIE as a keyword during the submission process. confirm that they have not previously published The Abstract Submission System has been optimized these data, that they have not previously presented for the current versions of most browsers: them at a large national annual scientific meeting, and that they are not planning to present or ★ Google Chrome: Version 23.0 or higher publish them prior to the dates of the AACR Annual ★ Internet Explorer: Version 9.0 or higher Meeting 2021. ★ Mozilla Firefox: Version 27.0 or higher Exception: Encore presentations are permitted for clinical trials abstracts that are submitted for the ★ Safari: Version 7.1 or higher January 11, 2021, clinical trials deadline. During the ★ Microsoft Edge: Version 79.0 or higher submission process, authors of encore clinical trials abstracts must provide the date and name Browsers should be set to enable JavaScript and to of the meeting at which the original trial abstract accept cookies. Users who need assistance in properly was presented. updating and configuring their browsers should contact Abstract Submission Customer Service at 217-398-1792 Content of Abstracts. Each abstract should contain or [email protected]. (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent Responsibilities of Authors. By submitting an experimental procedures; (c) a summary of the abstract for presentation at the AACR Annual Meeting, new, unpublished data; and (d) a statement of abstract authors agree and/or attest to the following: the conclusions. ★ Support for Abstract/Verification of Authorship. Abstracts should be carefully proofread to avoid All authors accept individual responsibility for errors in the published literature. American spelling the accuracy and integrity of statements in their should be used throughout; for more information abstract, and the submitting author is required regarding American spelling, please refer to Scientific to ensure that all authors have confirmed that Style and Format: The CSE Manual for Authors, all statements are an accurate reflection of the Editors, and Publishers, Eighth Edition (Council of presented data and have agreed to the submission Science Editors, 2014). of the abstract and to their being listed as contributors prior to submission. Authors will be Abstract Control Number. An Abstract Control notified of their inclusion on an abstract via email. Number (e.g., 21-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all ★ Sponsorship of Abstracts. The submitting author email correspondence regarding the abstract. Please must provide the name of an AACR member refer to the Abstract Control Number in any abstract who has agreed to sponsor the abstract, and the communications. submitting author must attest that the permission of the member sponsor has been secured prior to Financial Relationships of Coauthors. Per ACCME initiating an abstract submission. See page 18 for regulations, the AACR must collect information on the Abstract Sponsorship Regulations. financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships

AACR.org/AACR2021 ★ #AACR21 ★ 16 AACR ANNUAL MEETING 2021 GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS (cont’d) of each of your coauthors. For more information on abstracts after the November 19, 2020, deadline. financial relationships, visitAACR.org/CME. Note: Submitting an abstract for presentation Sponsor Permission and Information. Each abstract at the AACR Annual Meeting 2021 does not must be sponsored by an AACR member. You constitute registration for the meeting. Abstract must secure the permission of the sponsor before presenters must register to attend the meeting at submitting the abstract. For details, see the “Abstract AACR.org/AACR2021. Sponsorship Regulations” on page 18. Late-Breaking Abstract Deadline. The deadline for Length of Abstracts. The combined length of the late-breaking abstracts is 11:59 p.m. U.S. ET, Monday, abstract body, title, and tables may not exceed 2,600 January 11, 2021. Abstracts detailing highly characters, not including spaces and the author string. significant and timely findings in any area of cancer Tables count for 800 characters against the limit. research that were not available at the time of the Submission cannot be completed for abstracts that regular abstract deadline will be considered for exceed this limit. presentation at the Annual Meeting. Only those abstracts that are deemed to be of high scientific Abstract Category, Subcategory, and priority will be accepted. Subclassification. You must select a category, subcategory, and subclassification for your abstract. Abstract submission fees and sponsorship regulations See pages 19-23 for details. also apply to late-breaking abstracts.

Disclosure of Chemical Structures. At the time of Clinical Trials Abstract Deadline. All abstracts abstract submission, the submitting author is required describing clinical trials (including placeholder to state whether chemical compounds were used in the abstracts) should be submitted as late-breaking scientific work to generate the data in the proffered abstracts. The deadline for clinical trials abstracts is paper. Chemical compounds are defined as low- 11:59 p.m. U.S. ET, Monday, January 11, 2021. Final molecular-weight (generally <1000 g/mol) organic or data for placeholder abstracts are due Thursday, inorganic molecules, peptides, or proteins/nucleic acids February 4, 2021 (see page 9). Abstract submission cocrystallized with low-molecular-weight molecules. fees and sponsorship regulations also apply to clinical If chemical compounds were used, the corresponding trials abstracts. author is further required to indicate whether the Publication Opportunity. For consideration of complete chemical structures of the compounds used simultaneous publication in an AACR journal, please will be disclosed at the time of presentation at the contact the AACR Publishing Division at [email protected]. meeting. The chemical structures are not required to be included at the time of abstract submission; rather, an Presentation of Proffered Papers at the AACR Annual indication of the intent to disclose any such structures Meeting. Every proffered abstract that has been at the time of presentation is required. accepted for publication in the online Proceedings must have a corresponding presentation at the meeting. The Program Committee will then evaluate the Specifically, the author listed as the presenter for an information provided by the corresponding author accepted proffered paper must attend the corresponding and determine the acceptability of the proffered session to discuss in detail the research outlined in the paper for presentation. Those who do not intend to published abstract, according to the specific guidelines disclose chemical structures may have their abstracts of the session. Presentation formats for 2021 include rejected for participation; however, a limited number ePosters with enhanced engagement and networking of these abstracts without chemical structures may be opportunities and short talks in minisymposia. If, due to accepted for presentation if deemed to be of sufficient unforeseen circumstances, the designated presenter is scientific merit. unavailable to attend the session to present the paper, Submission Fee. Each abstract submitted must be he or she must contact the AACR Program Development accompanied by a $65 abstract submission fee. The Department to designate a coauthor to serve as submission fee can be paid by credit card or check. The the presenter. If no abstract authors are available fee is nonrefundable regardless of the final disposition to present the data, the presenter must withdraw of the abstract. the abstract immediately by contacting the AACR Program Development Department at 215-440-9300 or Abstract Deadline. The deadline for abstract [email protected]. Failure to comply with these submissions is 11:59 p.m. U.S. ET, Thursday, regulations pertaining to abstract presentation may November 19, 2020. Abstracts submitted after the result in actions including, but not limited to: deadline will not be considered by the Program Committee. No significant changes may be made to

AACR.org/AACR2021 ★ #AACR21 ★ 17 AACR ANNUAL MEETING 2021 GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS (cont’d)

★ The withdrawal of the abstract from the session AACR Member in good standing. (Student members are not eligible to sponsor an abstract.) ★ The removal of the abstract from the online Proceedings 2. An Active, Emeritus, or Honorary Member may sponsor an unlimited number of abstracts and may use his or ★ The loss of future sponsorship privileges for the her sponsorship privileges in two ways: (a) to sponsor sponsor of the abstract abstracts on which he or she is listed as an author, or ★ The loss of future abstract submission/authorship (b) to sponsor abstracts submitted by colleagues on privileges for the presenter of the abstract which he or she is not listed as an author.

Deadline for Withdrawal of Abstracts. Requests to 3. An Associate Member in good standing may withdraw regular abstracts will be accepted through sponsor one abstract for each submission deadline Monday, February 22, 2021. Requests to withdraw provided that (a) he or she is the presenter of the late-breaking or clinical trials abstracts will be abstract, and (b) an Active, Emeritus, or Honorary accepted through Tuesday, March 9, 2021. Withdrawal Member in good standing endorses the work. requests must be sent by email to abstractchanges@ Active, Emeritus, and Honorary Members may aacr.org. Withdrawal requests must include the endorse an unlimited number of abstracts while still Abstract Control Number and title as well as an retaining their right to sponsor an unlimited number explanation of the reason for withdrawal. of abstracts. 4. An Affiliate Member in good standing may sponsor one abstract for each submission deadline provided that he or she is the presenter of the abstract. ABSTRACT SPONSORSHIP (Affiliate Members are no longer required to provide REGULATIONS an endorser.) Expanded Abstract Sponsorship 5. Permission to list an AACR member as a sponsor Privileges for AACR Members or endorser must be obtained prior to selecting the sponsor/endorser in the Online Abstract Expanded abstract sponsorship privileges for selected Submission System. Individuals listed as sponsors AACR member types are available for the AACR or endorsers of abstracts will receive a notification Annual Meeting 2021, as outlined below: of sponsorship or endorsement via email. ★ Active, Honorary, and Emeritus Members may 6. The sponsor must verify the content, authenticity, now sponsor an unlimited number of abstracts for and quality of the abstract. Sponsorship of an presentation at the meeting. (As always, members abstract implies support for the data and the must verify the content, authenticity, and quality of interpretations contained therein. the abstracts they agree to sponsor.) COMPLIANCE WITH THESE REGULATIONS IS THE ★ Affiliate Membersare still permitted to sponsor RESPONSIBILITY OF THE AUTHORS. Adherence to one abstract for each deadline provided that they these rules will be strictly enforced. Violations will are the presenter of the abstract. However, Affiliate result in the rejection of the abstract by the Members are no longer required to provide an Program Committee. endorser for their abstract. Members must be in good standing in order to sponsor and endorse abstracts for presentation (see below for details). To be in good standing for the MEMBERSHIP APPLICATION November 19 regular abstract deadline, member dues must be paid in full through 2020. To be in good DEADLINES FOR ABSTRACT standing for the January 11 late-breaking and clinical SPONSORSHIP trials abstract deadline, member dues must be paid in Nonmember individuals interested in joining the AACR full through 2021. Associate, Honorary, and Emeritus and sponsoring an abstract for Annual Meeting 2021 Members are exempt from the payment of dues; must submit an application for membership no later than therefore, this regulation does not apply to them. November 12, 2020. Individuals interested in joining 1. Each abstract submitted for presentation at the the AACR and sponsoring a clinical trial or late-breaking AACR Annual Meeting must be sponsored by an abstract must submit an application for membership no Active, Emeritus, Honorary, Affiliate, or Associate later than January 7, 2021. Membership questions may be directed to [email protected].

AACR.org/AACR2021 ★ #AACR21 ★ 18 AACR ANNUAL MEETING 2021 ABSTRACT CATEGORIES

The 2021 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the Annual Meeting 2021. Please note that these abstract categories may or may not be used as Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification.The regular abstract submission deadline is Thursday, November 19, 2020 (11:59 p.m. ET) and the late-breaking and clinical trials abstract submission deadline is Monday, January 11, 2021 (11:59 p.m. ET).

The AACR is committed to raising awareness about the enormous public health challenge of cancer health disparities and racial inequalities. We encourage you to view the relevant abstract subcategories and subclassifications in the listing below. Also, a new submission category, COVID-19 and Cancer, provides an opportunity to submit novel work in this timely and critically important area.

MCB Molecular and Cellular Regulation of transcription factor function Large-scale approaches to cancer gene Biology, Genetics Transcriptional control of cell differentiation discovery Other Microarrays MCB01 Cell Growth Signaling Pathways Other Cell signaling MCB05 Epigenetics Cell-cell interactions Chromatin structure and function MCB10 microRNAs and Other Noncoding Growth factors DNA methylation RNAs GTPases, their regulators, and effectors Epigenetic changes as molecular markers Epigenetic control of miRNA expression Kinases and phosphatases of cancer miRNA profiling in cancer Receptors Epigenomics miRNA regulation of cancer biology Tumor-stromal cell interactions Gene silencing miRNA-based diagnostics Ubiquitin and ubiquitin-like proteins Histone modification miRNA-based therapeutics Other Other miRNAs as tumor suppressors/oncogenes Noncoding RNAs MCB02 Cell Death MCB06 Cell Cycle Other Apoptosis CDKs and CDK inhibitors Autophagy Cell cycle checkpoints MCB11 Cellular Stress Responses Bcl-2 family proteins Control of cell cycle progression Hypoxia Caspases Mitosis Oxidative stress Effectors of apoptosis Telomeres and telomerase Senescence Inhibitor of apoptosis (IAP) family proteins Other Unfolded protein response Necrosis and necroptosis Other Transcriptional control of apoptosis MCB07 DNA Damage and Repair Other Chromosomal structural alterations/ translocations MCB03 Oncogenes and Tumor Genomic instability BSB Bioinformatics, Suppressor Genes Homologous recombination Convergence Science, and Mechanisms of genomic alterations Cytoplasmic signal transducers Systems Biology Genotype/phenotype correlations Radiation-induced DNA damage Other Nuclear oncoproteins and tumor BSB01 Bioinformatics and Computational suppressor genes Biology Oncogene growth factors and their receptors MCB08 Metabolism and Cancer Metabolic pathways (See also MCB09: Genomics) Tumor suppressor genes Analytic pipeline optimization Other Metabolomics Mitochondrial function Application of bioinformatics to cancer biology Signaling pathways that regulate metabolism Database resources MCB04 Gene Regulation and Molecular modeling Transcription Factors Warburg effect Other New algorithms Chromatin structure and function New software for data analysis Gene expression Sequence analysis Mechanisms of transcription MCB09 Genomics (See also BSB01: Bioinformatics and Statistical methods Oncogenic transcription factors Other Posttranscriptional and translational control Computational Biology) Promoters and enhancers of transcription Functional genomics Protein-protein interactions in transcription Genomic profiling of tumors factor function High-throughput sequencing

AACR.org/AACR2021 ★ #AACR21 ★ 19 Regular Abstract Submission Deadline: AACR ANNUAL MEETING 2021 Thursday, November 19, 2020 ABSTRACT CATEGORIES (cont’d) Late-Breaking and Clinical Trials Abstract Submission Deadline: Monday, January 11, 2021

BSB02 Convergence Science and Systems TB06 Tumor Microenvironment TB10 Tumor Evolution and Biology Chemokines in the microenvironment Heterogeneity Artificial intelligence and machine learning Drug targets in the microenvironment Causes and consequences of tumor Integrative cancer biology Extracellular matrix and integrins heterogeneity Mathematical modeling Gene expression in the microenvironment Complex adaptive systems Network biology Immune cells in the tumor microenvironment Methods to measure tumor evolution Physical sciences and engineering Immunity and the microenvironment and heterogeneity Systems engineering Inflammatory cells as regulators of tumor Other Other growth Microbiome TB11 Carcinogenesis Organ-specific microenvironments Carcinogenesis: Chemical, environmental, TB Tumor Biology Proteases and inhibitors in the and molecular microenvironment Mutagenesis TB01 Nonclinical Models of Cancer Tumor dormancy Tumor initiation and promotion 3-D and tissue recombinant models Tumor/stromal interactions Viral-induced carcinogenesis Developmental phenotypes of cancer genes Tumor-immune system interactions Other Human-in-mouse models of human cancer Other Model organisms in drug discovery Mouse models of human cancer TB07 In Vivo Imaging CH Cancer Chemistry Noninvasive imaging in animal models (See also CL01: Translational Organoids Research – Molecular Biology in CH01 Drug Discovery, Design, Patient-derived xenograft models the Clinic) and Delivery Zebrafish models of cancer Advanced nanotechnology and imaging Basic and applied nanotechnology and Other animal and cell models of cancer Application of imaging technology to the clinic therapeutics Other Imaging in animal models Chemoinformatics, in silico screening, and Imaging of molecular and cellular events in the computational methods TB02 Stem Cell Biology tumor microenvironment Drug delivery Adult stem cells Imaging of molecular and cellular events in Drug design Cancer stem cells tumors and tumor cells High-throughput screening (assays and Developmental pathways in cancer Imaging the immune response libraries) Embryonic stem cells Imaging tumor metabolism Lead identification Stem cell markers New targets for imaging Lead optimization Stem cells and regenerative medicine in Other Nanotechnology drug delivery oncology Natural products Other TB08 Pediatric Cancer - Basic Science Synthesis, metabolism, and disposition (See also CL02: Pediatric Cancer - Other TB03 Tumor Adhesion Clinical Investigations; CT04: Cell adhesion and extracellular matrix Phase I, II, or III Clinical Trials in CH02 Structural and Chemical Biology Cell-cell adhesion Pediatric Cancer) Chemical genetics and genomics Drug resistance Developmental origins and drivers of pediatric Nanotechnology in chemical biology Other cancer Small molecule, protein, and nucleic acid Pediatric cancer epigenomics and genomics interactions TB04 Invasion and Metastasis Pediatric cancer models Target identification, small molecule probes, Actin cytoskeleton Pediatric cancer tumor microenvironment and and libraries Biomarkers of metastasis tumor heterogeneity X-ray and NMR structures Epithelial/mesenchymal transition (EMT Other Other and MET) Expression profiling of tumor progression TB09 Radiation Science CH03 Proteomics and Mass Spectrometry and metastasis (See also CL07: Radiation Oncology; Biological mass spectrometry and systems Genes that regulate migration and invasion ET09: Preclinical Radiotherapeutics) biology Imaging of tumor progression and metastasis Modulators of radiation response Proteomics and biomarker discovery Invasion and migration Photobiology/photodynamic therapy Proteomics and signaling networks Metastasis suppressor genes Radiation dose fractionation Other Metastasis-promoting genes Radiation-activated signaling pathways Premetastatic niche Radiation-induced gene expression Therapeutic metastasis prevention Radiation-induced resistance Other Radiobiology research Radioprotectors and radiosensitizers TB05 Angiogenesis Other Angiogenesis and angiogenesis inhibitors Host-tumor interactions Molecular mechanisms of angiogenesis Novel pro- and antiangiogenic factors Tumor microcirculation and the microenvironment Other

AACR.org/AACR2021 ★ #AACR21 ★ 20 Regular Abstract Submission Deadline: AACR ANNUAL MEETING 2021 Thursday, November 19, 2020 ABSTRACT CATEGORIES (cont’d) Late-Breaking and Clinical Trials Abstract Submission Deadline: Monday, January 11, 2021

ET Experimental and Molecular Topoisomerases IM02 Immunotherapy, Preclinical Therapeutics Tubulin agents and Clinical Tyrosine kinase and phosphatase inhibitors (See also CL06: Immuno-oncology; ET01 Drug Discovery Other ET07: Biological Therapeutic Antibody technologies Agents) Biochemical modulators of the therapeutic ET07 Biological Therapeutic Agents Adoptive cell therapy index (See also CL06: Immuno-oncology; Combination immunotherapies Combination chemotherapies IM02: Immunotherapy, Preclinical Immune checkpoints Differentiation therapy and Clinical) Immune mechanisms invoked by other New targets Antireceptors therapies including chemotherapy Novel assay technology Apoptosis: Therapeutic manipulation Immune mechanisms invoked by Novel drug delivery systems Growth factor receptors and other surface radiation therapy Targeting the tumor microenvironment in antigens as targets for therapy Immune monitoring/clinical correlates drug development Oncogenes, tumor suppressor genes, and gene Immune response to therapies Other products as targets for therapy Immunomodulatory agents and interventions Protein kinases and phosphatases as targets Inflammation, immunity, and cancer ET02 Mechanisms of Drug Action for therapy Modifiers of the tumor microenvironment Cell cycle mechanisms of anticancer drug Role of microenvironment in therapeutic Therapeutic antibodies, including engineered action response antibodies Cellular responses to anticancer drugs Other Vaccines (oncolytic and prophylactic) Interactions of new agents with radiation Other Role of the microenvironment in therapeutic ET08 Gene and Vector-Based Therapy response Antisense molecules Other Gene therapy and radiation studies Immune modulators CT Clinical Trials (including Combination and ET03 Drug Resistance Vector systems and targeting strategies Other Immunotherapy Trials) Drug resistance in molecular targeted therapies All clinical trials should be submitted Drug transport and metabolism by the January 11, 2021 clinical ET09 Preclinical Radiotherapeutics Novel mechanisms trials abstract deadline. Regulation of gene expression in drug (See also TB09: Radiation Science; resistance CL07: Radiation Oncology) Modification of radiosensitivity CT01 Phase I Adult Clinical Trials Reversal of drug resistance (See also ET05: Pharmacology, Other Molecular targets of radiation response Normal tissue/cellular stress responses to Pharmacogenetics, and Pharmacogenomics) ET04 Molecular Targets radiation Radioprotectors and radiosensitizers Cell death pathways and treatment CT02 Phase II Adult Clinical Trials Identification of molecular targets Radiotherapeutic combinations Other Modulation of DNA repair CT03 Phase III Adult Clinical Trials Molecular classification of tumors for diagnostics, prognostics, and therapeutic CT04 Phase I, II, or III Clinical Trials in outcomes IM Immunology Pediatric Cancer New nonclinical models for targets (See also CL02: Pediatric Cancer Other IM01 Tumor Immunobiology – Clinical Investigations; TB08: Adaptive immunity in tumors Pediatric Cancer – Basic Science) ET05 Pharmacology, Pharmacogenetics, Epigenetic regulation of tumor immunity Inflammation and cancer: Metastasis and Pharmacogenomics CT05 Phase I, II, or III Clinical Trials in Inflammation and cancer: Tumor initiation and (See also CT01: Phase I Adult the Elderly Clinical Trials) progression Innate immunity to tumors Cellular pharmacology CT06 Phase I, II, or III Clinical Trials Microbiome, inflammation, and cancer Molecular pharmacology in Minorities and Medically Novel animal models Pharmacogenetics and therapeutic response Underserved Populations Pharmacogenomics Oncogenic pathway-mediated regulation of Pharmacokinetics and pharmacodynamics inflammation and tumor immunity Preclinical toxicology Tumor antigenicity/processing and Other presentation Tumor-induced immune suppression: Extrinsic ET06 Small Molecule Therapeutic Agents factors DNA-reactive agents Tumor-induced immune suppression: Intrinsic Epigenetic targets factors HDAC and methyltransferase inhibitors Other Novel antitumor agents Novel targets and pathways PI3K/AKT inhibitors Proteasome inhibitors

AACR.org/AACR2021 ★ #AACR21 ★ 21 Regular Abstract Submission Deadline: AACR ANNUAL MEETING 2021 Thursday, November 19, 2020 ABSTRACT CATEGORIES (cont’d) Late-Breaking and Clinical Trials Abstract Submission Deadline: Monday, January 11, 2021

CT07 Clinical Trials for COVID-19 CL04 Clinical Research in Racial and CL09 Clinical Endocrinology [See also COVID06: Clinical Trials Ethnic Minorities and Other (See also EN01: Molecular, (Phase I–Phase IV and Trials in Underserved Populations Preclinical, and Clinical Progress)] Biobanking/biospecimen collection Endocrinology) Phase I Clinical trial design Endocrine-related cancers Phase II Community engaged research/community- Hormone receptors and diagnosis/prognosis Phase III based participatory research Hormone signaling and inhibitors Phase IV, observational, and expanded access Patient accrual and retention Hormone synthesis, metabolism, and inhibitors Clinical trials in progress Patient navigation Neuroendocrine and other endocrine factors Other Nuclear receptors: Structure and function CT08 Clinical Trials in Progress Preclinical studies of endocrine-related cancers Phase I clinical trials in progress CL05 Biostatistics in Clinical Trials Receptors and signal transduction Phase II clinical trials in progress Design and analysis of clinical trials Steroid hormone receptors Phase III clinical trials in progress New study designs: Theory, methodology, and Other modeling Statistical modeling for cancer studies CL10 Survivorship Research and CL Clinical Research Other Supportive Care [not including clinical trials; Biology of cell and tissue damage see also the Clinical Trials (CT) CL06 Immuno-oncology Comparative effectiveness research and categories] (See also ET07: Biological cost-effective studies Therapeutic Agents; IM02: Late effects and second cancers CL01 Translational Research – Molecular Immunotherapy, Preclinical and Psycho-oncology Biology in the Clinic Clinical) Supportive care, palliation, and pain (See also: TB07: In Vivo Imaging) Adoptive cell therapy management Clinical imaging Combination immunotherapies Translational survivorship research Cytogenetics and clinical molecular genetics Immune checkpoints Other Epigenetic therapy Immune mechanisms invoked by other Functional and molecular imaging therapies including chemotherapy CL11 Biomarkers Laboratory correlates for targeted agents Immune mechanisms invoked by Biomarkers predictive of therapeutic benefit Molecular classification of tumors radiation therapy Diagnostic biomarkers Radiomics Immune monitoring/clinical correlates Early detection biomarkers Tumor staging: Correlation of clinical and Immune response to therapies Liquid biopsies: Circulating DNA molecular markers Immunomodulatory agents and interventions Liquid biopsies: Circulating tumor cells Other Inflammation, immunity, and cancer Metastasis biomarkers Modifiers of the tumor microenvironment Prognostic biomarkers CL02 Pediatric Cancer – Therapeutic antibodies, including engineered Other Clinical Investigations antibodies (See also CT04: Phase I, II, or III Vaccines (oncolytic and prophylactic) CL12 Clinical Outcomes Research Clinical Trials in Pediatric Cancer; Other Clinical outcomes research TB08: Pediatric Cancer – Basic Science) CL07 Radiation Oncology Adolescent and young adult oncology (See also TB09: Radiation Science; EN Endocrinology Childhood cancer drug development ET09: Preclinical Radiotherapeutics) Immunotherapeutic approaches to pediatric Clinical radiotherapeutic studies EN01 Molecular, Preclinical, and cancer Interventional radiology Clinical Endocrinology Pediatric cancer predisposition and surveillance Modification of radiosensitivity (See also CL09: Clinical Survivorship, late effects, and secondary Radiation-immunotherapy and other Endocrinology) cancers radiotherapeutic combinations Endocrine-related cancers Therapeutic dosing, resistance, and Radiation-induced late effects/secondary Growth factors, receptors, and signal combination therapy approaches in cancers transduction pediatric oncology Radiation-induced resistance Hormone receptors and diagnosis/prognosis Translational pediatric cancer research Other Hormone signaling and inhibitors Other Hormone synthesis, metabolism, and inhibitors CL08 Surgical Oncology (including Neuroendocrine and other endocrine factors CL03 Clinical Research in the Elderly Prophylactic Surgery) Nuclear receptors: Structure and function Aging, immunity, and cancer Surgical oncology Preclinical studies of endocrine-related cancers Other Receptors and signal transduction Steroid hormone receptors Other

AACR.org/AACR2021 ★ #AACR21 ★ 22 Regular Abstract Submission Deadline: AACR ANNUAL MEETING 2021 Thursday, November 19, 2020 ABSTRACT CATEGORIES (cont’d) Late-Breaking and Clinical Trials Abstract Submission Deadline: Monday, January 11, 2021

EP Epidemiology (including Genetic markers as surrogate endpoints in Palliative care Genetic, Molecular, and prevention trials Patient management Genomics and proteomics in cancer risk and Treatment modifications Integrative Epidemiology) response assessment Other Infections and viral-related cancers EP01 Epidemiology Microbiome and prevention COVID08 Effects of COVID-19 on Biomarkers of endogenous or exogenous Prevention and treatment of premalignant Cancer Survivorship exposures, early detection, and biologic effects lesions (intraepithelial neoplasia) Long-term health-related quality of life issues Biomarkers of prognosis Prevention of second cancers Psychosocial impact on patients and health care Cancer health disparities research Recruitment of racial and ethnic minorities workers Descriptive epidemiology, covering cancer and other underserved populations in clinical Other incidence, mortality, clusters, and trends prevention trials Diet, alcohol, tobacco use, and other lifestyle Screening and early detection COVID09 Risk Factors and Comorbidities risk factors Other Resulting in Adverse Outcomes for Environmental and occupational risk factors Cancer Patients with COVID-19 Familial and hereditary cancers PR03 Implementation Science Functional studies of genetic variants Behavioral science and prevention COVID10 Cancer Prevention and Early Gene-gene and gene-environment interactions Cancer communication and decision-making Detection during the COVID-19 Genome-wide association studies (GWAS)/ Cancer health disparities research Pandemic post-GWAS Genetic testing and counseling Health services and comparative effectiveness Health policy and outcomes COVID11 Epidemiology and Registries of research Obesity, diet, physical activity, and energy COVID-19 and Cancer (including Infection and immune factors balance Biorepositories) Next-generation sequencing in epidemiology Quality of life/late effects/survivorship studies (whole genome, exome, targeted, or Other COVID12 Health Inequalities and Disparities fine-mapping) during the COVID-19 Pandemic Pathway and candidate gene studies of risk or prognosis COVID13 Science and Public Policy Pharmacoepidemiology COVID COVID-19 and Cancer Effects of regional public health policies Preneoplastic and tumor markers Funding Primary and secondary intervention studies COVID01 Intersection of the Biology of Regulatory science and policy Risk prediction models for incidence, prognosis, SARS-CoV-2 and Cancer Workforce and/or mortality Biomarkers/predictors of COVID-19 Other Screening and early detection and cancer Statistical and epidemiological methodology Host genomics and genetics Survivorship research Immunobiology Other Pathophysiology RSP Regulatory Science Viral evolution and Policy Other PR Prevention, Early Detection, RSP01 Regulatory Science and Policy COVID02 Diagnostics for COVID-19 Testing: Biosimilars and generics and Interception Design, Development, and Clinical trial design and accrual Validation Combination therapies and codevelopment of PR01 Preclinical Prevention, Early investigational agents and diagnostics Detection, and Interception COVID03 Cancer Drug Repurposing to Treat Data science and informatics Animal models in prevention COVID-19 Novel endpoints and biomarkers Biological and biochemical mechanisms in Real-world evidence and retrospective analyses prevention COVID04 COVID-19 Vaccine Development Tobacco and e-cigarette regulation Biomarkers and intervention studies Other Cellular models COVID05 Effects of Cancer Immunotherapies Chemoprevention studies on Patients with COVID-19 (with or Diet, nutrition, and cancer without Cancer) Microbiome and prevention SHP Science and Health Policy Molecular markers in prevention research COVID06 Clinical Trials SHP01 Science and Health Policy Molecular targets for prevention [See also CT07: Clinical Trials for New agent development Cancer health disparities COVID-19 (Phase I–Phase IV and Cancer survivorship Screening and early detection Trials in Progress)] Other Comparative effectiveness research Phase I Implementation science Phase II Patient advocacy and engagement PR02 Clinical Prevention, Early Detection, Phase III and Interception Value and cost issues in cancer care Phase IV, observational, and expanded access Other Application of molecular pathology in Clinical trials in progress clinical prevention Biomarkers and intervention studies COVID07 Continuity of Cancer Care Cancer health disparities research Long-term cancer outcomes Cancer surveillance and screening studies Novel health care strategies (including telehealth Chemoprevention clinical trials and digital health)

AACR.org/AACR2021 ★ #AACR21 ★ 23 AACR ANNUAL MEETING 2021 AACR MEMBERSHIP OPPORTUNITIES

AACR MEMBERSHIP: ABSTRACT SPONSORSHIP THE ESSENTIAL ASSOCIATION Membership Application Abstract FOR YOU Deadlines Deadlines With over 47,000 members in 127 countries and November 12, November2020 19, 2020 territories around the world, the AACR is a dynamic and vibrant organization that offers its members January 7, 2021 January 11, 2021 opportunities to participate more fully in the global (Late-Breaking and initiative to eliminate cancer. AACR membership Clinical Trials) is available to those who conduct cancer research and related biomedical science, both senior and SCHOLAR AWARDS early-career investigators, as well as to those health care professionals, research administrators, cancer Membership Application All Travel Awards survivors and advocates, students, and others who Deadline Application Deadline share the AACR’s vision and support our mission to November 12, November2020 19, 2020 accelerate the prevention and cure of all cancers. Contact the AACR Membership Department with any AACR membership categories promote the questions at 215-440-9300 or [email protected]. professional growth of those in training, facilitate collaborations for established scientists, and provide support for all working in cancer research. Special rates are available to members located in countries with emerging economies as designated by the World Bank. For a complete list of countries with emerging AACR MEMBERSHIP CATEGORIES economies, please visit AACR.org/International. Active Membership is open to investigators worldwide who have established a record of scholarly activity resulting in original peer-reviewed articles in publications relevant to cancer research and biomedical science. MEMBERSHIP APPLICATION DEADLINES FOR ABSTRACT Affiliate Membershipis open to qualified individuals SPONSORSHIP who are health professionals working in support of cancer research and biomedical science; survivors and Nonmember individuals interested in joining the advocates who are members of organizations whose AACR and sponsoring an abstract must submit mission includes the advancement of cancer research; an application for membership no later than educators; or other professionals who are interested November 12, 2020. Individuals interested in joining in and/or make substantial contributions to the cancer the AACR and sponsoring a late-breaking abstract field. must submit an application for membership no later than January 7, 2021. Associate Membership is open to graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to careers in cancer research and the related sciences. Annual dues are not required.

AACR.org/AACR2021 ★ #AACR21 ★ 24 AACR ANNUAL MEETING 2021 AACR MEMBERSHIP OPPORTUNITIES (cont’d)

Student Membership is open to persons who Honorary Membership is open to distinguished have manifested an interest in cancer and the individuals who have made extraordinary related biomedical sciences and who are enrolled contributions to the advancement of cancer research in a program leading to a high school diploma or a either through outstanding personal scientific activity bachelor’s degree. Annual dues are not required. or through exceptional leadership in cancer research. (Candidates for Honorary Membership are invited Sustaining Membership is open to organizations in through a special selection process.) recognition of annual payment of dues and other substantial contributions in support of the mission, Please contact the Membership Department at purposes, and activities of the Association. Annual [email protected] or 215-440-9300 and a dues are determined by the Sustaining Member level. membership representative will gladly assist with any questions. Not yet a member? Apply for Emeritus Membership is open to existing Active membership at myAACR and join us in the global Members who have reached the age of 70 years, who conquest of cancer. are disabled, or who are retired.

“The knowledge shared by researchers all around the world helped me in understanding the current landscape of cancer research.”

AACR.org/AACR2021 ★ #AACR21 ★ 25 AACR ANNUAL MEETING 2021 GENERAL INFORMATION

ABOUT WASHINGTON, DC FELLOWS OF THE AACR ACADEMY Washington, DC, the nation’s capital and the political focal point of the country, hosts 176 foreign The AACR Academy was established in 2013 to embassies as well as the headquarters of many honor distinguished scientists whose major scientific international organizations, trade unions, nonprofit contributions have propelled significant innovation organizations, advocacy groups, and professional and progress against cancer. Those elected, known associations. Home to a lively urban center, as Fellows of the AACR Academy, constitute a Washington, DC, is a walkable city that offers a variety global brain trust of individuals who are instrumental of dining options and numerous free attractions, in advancing the mission of the AACR to prevent museums, and historical monuments. The Georgetown and cure all cancers through research, education, Lombardi Comprehensive Cancer Center, the George communication, and collaboration. Washington University Cancer Institute, the National Cancer Institute, the National Institutes of Health, The AACR Academy is currently led by Dr. Judy E. the U.S. Food and Drug Administration, and other Garber and a Steering Committee of ten additional government agencies that are important to the cancer Fellows who serve as a voice for all Fellows of the field are all located in Washington, DC, and the region. AACR Academy, while providing ongoing advice and counsel to the AACR leadership on timely and significant scientific and policy topics as well as other matters of importance to the cancer field.

The next elected class of Fellows of the HOUSING AND REGISTRATION AACR Academy will be formally recognized in conjunction with the AACR Annual Meeting 2021 Housing and registration for AACR Annual Meeting Opening Ceremony scheduled to take place on 2021 will open in December. Additional information Sunday, April 11. will be posted at AACR.org/AACR2021.

AACR SCIENTIFIC ACHIEVEMENT OPPORTUNITIES TO SUPPORT AWARDS, LECTURESHIPS, THE AACR FOUNDATION AND PRIZES The AACR Foundation welcomes support from In 1961, the AACR established its first scientific corporations, foundations, individuals, and other achievement award, partnering with Eli Lilly and organizations that share its mission and are interested Company to present the AACR G.H.A. Clowes in helping to defray the costs of presenting this Memorial Award. Named for G.H.A. Clowes, a important international meeting on the latest founding member of the AACR and a past research developments in cancer research. For a complete list director at Eli Lilly and Company, the award was of support opportunities and their many benefits, created to recognize an individual scientist for please contact Peter VanPelt, Senior Director, outstanding recent accomplishments in the field of Corporate and Foundation Relations, at 215-446-7256 basic cancer research. or via email at [email protected].

AACR.org/AACR2021 ★ #AACR21 ★ 26 AACR ANNUAL MEETING 2021 GENERAL INFORMATION (cont’d)

More than fifty years later, the AACR continues to EXHIBIT SHOW recognize and reward scientific excellence in all areas of cancer research by annually administering The 2021 AACR Exhibit Show will include a wide array 19 different scientific achievement awards and of companies with the latest products and services for lectureships. In addition to these awards, the AACR laboratory and clinical research. If your organization annually presents the AACR June L. Biedler Prize for would like to exhibit and would like to receive an Cancer Journalism, which since 2015 has recognized Exhibitor Prospectus, please contact the Exhibits Team outstanding journalistic coverage that enhances the at 215-440-9300 or by email at [email protected]. general public’s understanding of cancer science and medicine.

All 2020-2021 AACR awardees will be formally recognized throughout the AACR Annual Meeting 2021, with the majority of individuals presenting ASSISTANCE FOR PHYSICALLY featured scientific lectures highlighting their CHALLENGED REGISTRANTS research accomplishments. We encourage you to attend these lectures and also to nominate your The AACR Annual Meeting is accessible to all colleagues for one or more of these prestigious attendees. Registrants with special requirements awards at AACR.org/Awards. for transportation, hotel accommodations, or other facilities connected with the meeting should notify the AACR in advance by checking the appropriate box when registering and providing the necessary details or by emailing the Meetings and Exhibits Department at [email protected]. SATELLITE EDUCATIONAL SYMPOSIA

Satellite Educational Symposia will be held in conjunction with the AACR Annual Meeting. These CME-accredited events are supported by parties other than AACR and are not part of the official program of the AACR Annual Meeting. Symposia are evaluated by the Satellite Educational Symposia Committee to ensure that the educational content will enhance that provided by the official AACR scientific program. Additional information will be available at AACR.org/AACR2021.

2020

AACR VIRTUAL ANNUAL MEETINGS I AND II “Exceptional during this unexpected hard time.”

AACR.org/AACR2021 ★ #AACR21 ★ 27 AACR ANNUAL MEETING 2021 COMMITTEES

AACR ANNUAL MEETING AACR EDUCATION COMMITTEE PROGRAM COMMITTEE Chair Chair Roger S. Lo Charles Swanton Additional Appointments Pending Vice Chairs Lewis C. Cantley Heather R. Christofk AACR CLINICAL TRIALS Melissa B. Davis COMMITTEE Keith T. Flaherty Ricky W. Johnstone Cochairs Karen E. Knudsen Julie R. Brahmer Quynh-Thu Le Manuel Hidalgo Jean-Charles Soria Louis M. Staudt Members David A. Tuveson Stephen B. Baylin Joseph N. Contessa Cochairs Johann S. de Bono Peter C. Adamson Stephan A. Grupp Carole L. Baas Susan Halabi Dafna Bar-Sagi Matthew D. Hellmann David L. Bartlett Corey J. Langer Julie R. Brahmer Malcolm J. Moore Javier Cortés Kunle Odunsi Riccardo Dalla-Favera Pamela S. Ohashi Luis A. Diaz Suresh S. Ramalingam John F. DiPersio Russell J. Schilder Steven M. Dubinett Yu Shyr Tariq Enver Mark A. Socinski Douglas T. Fearon Roger Stupp Irene M. Ghobrial Weijing Sun Anna R. Giuliano Charles Swanton W. Nicholas Haining Dan Theodorescu James R. Heath Brian Andrew Van Tine Manuel Hidalgo Ignacio I. Wistuba Melissa M. Hudson Stephen Yip Stephen D. Hursting Christine A. Iacobuzio-Donahue Additional Appointments Pending Roger S. Lo Elli Papaemmanuil David Pellman Erik Sahai Stephen P. Schoenberger Shelley S. Tworoger Roel Verhaak Jane E. Visvader

AACR.org/AACR2021 ★ #AACR21 ★ 28